理解嗜色性肾细胞癌中 m6A 的变化并预测患者预后生存。
Understanding m6A changes in chromophobe renal cell carcinoma and predicting patient outcomes survival.
机构信息
Department of Urology, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), Beijing, 100080, China.
Synthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China.
出版信息
BMC Cancer. 2024 Sep 27;24(1):1187. doi: 10.1186/s12885-024-12956-6.
N6-methyladenosine (mA) is a prevalent mRNA modification known for its implications in various cancer types, yet its role in chromophobe renal cell carcinoma (chRCC) remains largely unexplored. In this study, we performed m6A-SEAL-seq and RNA-seq analyses on tissues from three chRCC subjects, aiming to uncover mA alterations in chRCC. Our findings revealed reduced expression levels of four mA regulators in chRCC tissues and highlighted differences in mA levels compared to normal tissues. Furthermore, we identified specific genes and cancer-related pathways affected by these differences, including notable candidates like NOTCH1 and FGFR1, implicated in chRCC development. Additionally, we developed a predictive model based on the expression level of mA associated genes, demonstrating promising prognostic capabilities for patient survival prediction. Overall, our study provides valuable insights into the role of mA in chRCC and its potential as a prognostic indicator.
N6-甲基腺苷（m6A）是一种普遍存在的 mRNA 修饰物，其在各种癌症类型中的作用已得到广泛研究，但在嗜铬细胞瘤肾细胞癌（chRCC）中的作用仍知之甚少。在这项研究中，我们对三名 chRCC 患者的组织进行了 m6A-SEAL-seq 和 RNA-seq 分析，旨在揭示 chRCC 中的 mA 改变。我们的研究结果表明，chRCC 组织中四种 mA 调节剂的表达水平降低，并突出了与正常组织相比 mA 水平的差异。此外，我们还确定了受这些差异影响的特定基因和癌症相关途径，包括在 chRCC 发育中起重要作用的候选基因，如 NOTCH1 和 FGFR1。此外，我们还基于 mA 相关基因的表达水平开发了一个预测模型，该模型在预测患者生存方面具有有前景的预后能力。总的来说，我们的研究为 mA 在 chRCC 中的作用及其作为预后指标的潜力提供了有价值的见解。
Zotero 插件